Lynpraza Olaparib 150Mg Tablets

150Mg Tablets, Box

4.5 (154)

180,000

Lynpraza Olaparib 150mg Tablet is a PARP inhibitor developed by AstraZeneca, approved for BRCA-mutated advanced ovarian cancer. It was first approved by the FDA in December 2014 as a monotherapy for patients with germline BRCA-mutated ovarian cancer who had already received multiple prior chemotherapy treatments, and the European Commission granted similar approval the same month for maintenance therapy in platinum-sensitive relapsed cases.

Description

Introduction Of Lynpraza Olaparib 150mg Tablet:

Lynpraza Olaparib 150mg Tablet, discovered and developed by AstraZeneca, was the first PARP inhibitor drug approved for germline BRCA-mutated advanced ovarian cancer. It works by blocking an enzyme called PARP, which helps cancer cells repair damaged DNA — preventing this repair causes cancer cells to die and slows tumor growth.

Regulatory Approval History :

The US Food and Drug Administration (FDA) approved Lynpraza Olaparib 150mg Tablet in December 2014 as a monotherapy for patients with germline BRCA-mutated advanced ovarian cancer who had already received at least three prior lines of chemotherapy. This accelerated approval was based on results from Phase II clinical trials, with Phase III trials continuing to confirm clinical benefit.

The European Commission also granted marketing authorization in December 2014 for maintenance therapy in adult patients with platinum-sensitive relapsed BRCA-mutated high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who had responded to platinum-based chemotherapy.

Uses of Lynpraza Olaparib 150mg Tablet :

  • BRCA-mutated advanced ovarian cancer
  • Maintenance therapy for platinum-sensitive relapsed ovarian cancer

How to Take Lynpraza Olaparib 150mg Tablet :

This tablet should be taken exactly as prescribed by your doctor, typically twice daily. It can be taken with or without food, but try to take it at the same time each day for the best results. Do not stop taking it unless your doctor advises you to, as consistent use is important for effectiveness.

Mechanism of Action of Lynpraza Olaparib 150mg Tablet :

Lynpraza Olaparib 150mg Tablet works by inhibiting PARP enzymes, which play a role in repairing damaged DNA in cells. By blocking this repair process in cancer cells — particularly those with BRCA gene mutations — it leads to the destruction of cancer cells. For more clinical details, refer to MedlinePlus Drug Information, a trusted resource from the U.S. National Library of Medicine.

Common Side Effects :

Common side effects include fatigue, anemia, decreased appetite, and respiratory tract infections. Your doctor will monitor you closely and provide guidance on managing any side effects that arise.

Contact Us

Info Table
Packaging Size Strip
Brand Lynpraza150mg Tablets
Composition Olaparib 150mg
Manufacturer AstraZeneca
Treatment CANCER
Prescription/Non prescription Prescription
Vendor Info
Benefits
Reviews

Description

Introduction Of Lynpraza Olaparib 150mg Tablet:

Lynpraza Olaparib 150mg Tablet, discovered and developed by AstraZeneca, was the first PARP inhibitor drug approved for germline BRCA-mutated advanced ovarian cancer. It works by blocking an enzyme called PARP, which helps cancer cells repair damaged DNA — preventing this repair causes cancer cells to die and slows tumor growth.

Regulatory Approval History :

The US Food and Drug Administration (FDA) approved Lynpraza Olaparib 150mg Tablet in December 2014 as a monotherapy for patients with germline BRCA-mutated advanced ovarian cancer who had already received at least three prior lines of chemotherapy. This accelerated approval was based on results from Phase II clinical trials, with Phase III trials continuing to confirm clinical benefit.

The European Commission also granted marketing authorization in December 2014 for maintenance therapy in adult patients with platinum-sensitive relapsed BRCA-mutated high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who had responded to platinum-based chemotherapy.

Uses of Lynpraza Olaparib 150mg Tablet :

  • BRCA-mutated advanced ovarian cancer
  • Maintenance therapy for platinum-sensitive relapsed ovarian cancer

How to Take Lynpraza Olaparib 150mg Tablet :

This tablet should be taken exactly as prescribed by your doctor, typically twice daily. It can be taken with or without food, but try to take it at the same time each day for the best results. Do not stop taking it unless your doctor advises you to, as consistent use is important for effectiveness.

Mechanism of Action of Lynpraza Olaparib 150mg Tablet :

Lynpraza Olaparib 150mg Tablet works by inhibiting PARP enzymes, which play a role in repairing damaged DNA in cells. By blocking this repair process in cancer cells — particularly those with BRCA gene mutations — it leads to the destruction of cancer cells. For more clinical details, refer to MedlinePlus Drug Information, a trusted resource from the U.S. National Library of Medicine.

Common Side Effects :

Common side effects include fatigue, anemia, decreased appetite, and respiratory tract infections. Your doctor will monitor you closely and provide guidance on managing any side effects that arise.

Contact Us

Reviews

There are no reviews yet.

Be the first to review “Lynpraza Olaparib 150Mg Tablets”

Your email address will not be published. Required fields are marked *

Frequently Asked Questions

From sourcing to delivery, we ensure reliability at every step. Our operations follow strict quality and regulatory standards.

What is Lynpraza Olaparib 150mg Tablet used for?
Lynpraza Olaparib Tablet is used to treat BRCA-mutated advanced ovarian cancer and as maintenance therapy for platinum-sensitive relapsed cases.
It was first approved by the FDA and the European Commission in December 2014.
It works by inhibiting PARP enzymes, blocking DNA repair in cancer cells and leading to their destruction. For more clinical details, see MedlinePlus Drug Information.
It’s indicated for patients with germline BRCA mutations, typically after multiple prior lines of chemotherapy.
Common side effects include fatigue, anemia, decreased appetite, and respiratory tract infections.
Lynpraza Olaparib Tablet is manufactured by AstraZeneca, supplied as a box of tablets.

Related products